A Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Not yet recruiting
Merck Sharp & Dohme Corp.
The primary objective of this study is to compare MK-6482 to everolimus with respect to
progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1
(RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare
everolimus with respect to overall survival (OS). The hypothesis is that MK-6482 is superior
to everolimus with respect to PFS and OS.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.